Skin & hair

Apremilast, the Pill Between Creams and Biologics

Save

Not every step up from a psoriasis cream has to be an injection. Apremilast is an oral pill that occupies a specific rung on the treatment ladder, positioned after topical and light-based treatment but generally considered a lighter-touch option than the biologics that follow it. Here is what that positioning actually means, and where the ladder leads if a pill isn't enough.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Where Apremilast Sits on the Psoriasis Treatment Ladder

The psoriasis treatment ladder generally begins with topical therapy — corticosteroids and steroid-sparing agents like vitamin D analogs — for limited, non-intertriginous plaques 1. Apremilast enters the picture once topical treatment alone isn't controlling enough of the skin, typically for moderate disease that covers more body surface than topicals can reasonably treat, but before a clinician and patient decide an injectable biologic is warranted. It occupies a specific niche: a systemic option, meaning it works through the whole body rather than just the skin it's applied to, but one delivered as a daily pill rather than a shot or infusion. That distinction is often the deciding factor for people choosing between apremilast and a biologic at this stage. Some people move onto apremilast directly from topical treatment; others try it after phototherapy hasn't fit their schedule or hasn't cleared enough skin, since the ladder isn't a strict single-file line so much as a set of options grouped by how much they ask of the body and the calendar.

What Apremilast Actually Is

Apremilast works by blocking phosphodiesterase-4, an enzyme involved in the inflammatory signaling that drives psoriasis plaques, which is a different mechanism than either the biologics that target specific immune proteins or the topical steroids that dampen inflammation locally. It's taken by mouth on a regular schedule rather than injected, which is the main practical appeal: no needles, no refrigeration, no infusion appointments. That convenience comes with a tradeoff worth naming honestly — oral small-molecule drugs like apremilast tend to clear psoriasis less completely, on average, than the biologics used later on the ladder, which is part of why it's generally positioned as a middle step rather than a replacement for biologic therapy in more severe disease.

How It Compares to Topical and Light-Based Treatment

Topical corticosteroids and vitamin D analogs remain the standard first step for limited plaques, with topical treatment escalated before systemic options are considered 1. Phototherapy — narrowband UVB, broadband UVB, or PUVA — is another non-systemic option for more widespread disease, delivered in a clinic or with a home unit, and guidelines describe it as effective with a well-characterized safety and dosing profile 2. Apremilast becomes relevant when topical treatment can't reasonably cover the amount of affected skin and phototherapy isn't practical or hasn't worked well enough — the point at which staying with topical-only treatment starts costing more in daily effort than it returns in clearance.

Why Comorbidities Shape the Decision

Guidelines recommend that people with psoriasis be screened for related conditions — psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity — as part of ongoing care, not just at diagnosis 3. That screening matters directly when choosing a systemic treatment: psoriasis itself is associated with a higher risk of cardiovascular disease, with the association strongest in more severe disease 4. Comorbidity screening isn't a side note to psoriasis treatment — it actively shapes which systemic option makes sense for a given person. None of this means apremilast is chosen or avoided because of cardiovascular risk specifically; it means the fuller health picture, not just how the skin looks, is part of what a dermatologist weighs before settling on any systemic option, apremilast included.

Apremilast and Joint Disease

Psoriatic arthritis changes the calculation. When joints are involved and disease is active, treatment guidelines for psoriatic arthritis have generally favored TNF-inhibitor biologics over oral small-molecule options as first-line therapy 5. That guideline preference for biologics in active joint disease is a meaningful data point for anyone with both skin and joint symptoms weighing an oral option against an injectable one — it doesn't rule out an oral small molecule, but it does mean the joints, not just the skin, belong in the conversation with a rheumatologist or dermatologist before deciding. Skin-only psoriasis and psoriasis with joint involvement are, in this sense, two different decisions wearing the same name, and it's worth being explicit with a clinician about which one is actually being treated.

When Apremilast Isn't Enough

If plaques stay active on apremilast after a fair trial, the next step is usually a biologic — TNF, IL-17, IL-23, or IL-12/23 inhibitors, delivered by injection or infusion, which guidelines support with detailed dosing and safety-monitoring recommendations for exactly this kind of escalation 6. Choosing among the psoriasis biologics involves its own set of tradeoffs around speed of response, infection risk, and dosing frequency, which is a separate decision from the one between topical treatment and apremilast, and usually a longer conversation than the one that led to trying apremilast in the first place. Recognizing when psoriasis creams — or an oral option like apremilast — have stopped working is really a question of how much skin is still affected and how much that's affecting daily life, not a fixed percentage anyone can set in advance.

Matching the Step to How Severe Psoriasis Actually Is

How psoriasis severity is measured — generally through body surface area and plaque characteristics — is what actually anchors where someone sits on this ladder, more than how long they've had the condition or how it looked at diagnosis. Mild disease often stays on topicals indefinitely; moderate disease is where apremilast and phototherapy both become reasonable options; severe disease, joint involvement, or a strong impact on quality of life is where the guideline evidence more clearly favors biologics. Revisiting that severity assessment periodically, rather than assuming the original treatment tier is permanent, is what keeps the ladder working as intended. Psoriasis also fluctuates on its own, with flares and quieter stretches independent of treatment, so a single bad month is less informative than a pattern tracked over several visits.

Common questions

No. Apremilast is an oral small-molecule drug, taken as a pill, while biologics are proteins given by injection or infusion. They work through different mechanisms and sit at different points on the psoriasis treatment ladder, with apremilast generally considered before biologics for moderate disease.

On average, oral options like apremilast tend to clear psoriasis less completely than biologics, which is part of why it's typically positioned as a middle step. Individual results vary, and some people do very well on it; a dermatologist can set realistic expectations based on how much skin is affected.

Apremilast is used for joint symptoms in some cases, but guidelines for active psoriatic arthritis have generally favored TNF-inhibitor biologics as first-line therapy over oral small-molecule options. Whether an oral option is reasonable for a particular case of joint involvement is worth discussing with a rheumatologist or dermatologist directly.

The usual next step is a biologic — a TNF, IL-17, IL-23, or IL-12/23 inhibitor — chosen based on disease severity, other health conditions, and how quickly relief is needed. Moving to a biologic after apremilast is a common, expected step on the ladder, not a sign apremilast failed in some unusual way.

The most common reasons are avoiding injections, avoiding the monitoring and infusion logistics some biologics involve, or having moderate disease that doesn't yet warrant a biologic's stronger effect and different risk profile. It's a preference-and-severity decision made with a dermatologist rather than a one-size answer.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When psoriasis needs more than the current plan

  • —Joint pain, stiffness, or swelling alongside skin plaques, which can signal psoriatic arthritis
  • —Plaques covering a rapidly increasing amount of the body, or widespread redness and scaling
  • —New or worsening depression, anxiety, or mood changes while on any psoriasis treatment
  • —Signs of infection — fever, spreading warmth or redness, or a wound that isn't healing — while on a systemic medication

This article is general health information, not medical advice. It cannot determine whether apremilast, a biologic, or another treatment is right for your psoriasis. A dermatologist who knows your health history and disease severity is the right source for that decision.

References

  1. 1.American Academy of Dermatology; National Psoriasis Foundation (2021). Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology. PMID 32738429 ✓Topical corticosteroids for non-intertriginous plaques and steroid-sparing agents like vitamin D analogs are the first-line topical step of the psoriasis treatment ladder, escalated before systemic options.
  2. 2.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. PMID 31351884 ✓Phototherapy (narrowband/broadband UVB, PUVA) is an effective, well-characterized non-systemic option for more widespread psoriasis on the treatment ladder.
  3. 3.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. PMID 30772097 ✓Guidelines recommend screening people with psoriasis for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity as part of ongoing care.
  4. 4.Garshick MS, Ward NL, Krueger JG, Berger JS (2021). Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. Journal of the American College of Cardiology. doi:10.1016/j.jacc.2021.02.009Psoriasis is associated with increased cardiovascular disease risk driven by systemic inflammation, with the association strongest in more severe disease.
  5. 5.Singh JA, Guyatt G, Ogdie A, et al. (2019). 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care & Research / Arthritis & Rheumatology. PMID 30499246 ✓Guidelines for active psoriatic arthritis conditionally recommend TNF-inhibitor biologics over oral small-molecule drugs as first-line therapy.
  6. 6.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. PMID 30772098 ✓Biologic agents (TNF, IL-17, IL-23, IL-12/23 inhibitors) are supported by guideline recommendations on efficacy, dosing, and safety monitoring for the biologic tier of the psoriasis treatment ladder.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library